All inspectors · Key sources (PDF) · Antithrombotics sheet (PDF)
The Antithrombotic Therapy Around PCI one-pagerOpen it in a new tab

The patient in front of you

Mrs. K., 77, with hypertension, presented with 5 hours of chest pain at rest, ST depression in V2–V4 and a rising troponin. Angiography the next day showed a single 90% stenosis of the proximal left anterior descending artery, treated with a drug-eluting stent by radial access. She was loaded with aspirin and ticagrelor. She has never bled and takes no anticoagulant; eGFR 48, hemoglobin 12.6 g/dL, platelets 214, ejection fraction 55%, sinus rhythm. She went home on day 2. Three weeks after PCI, new atrial fibrillation was found (nothing else changed): a DOAC was started, ticagrelor was changed to clopidogrel and aspirin was stopped, and she has taken the DOAC and clopidogrel since. Today is her 12-month visit: she is stable and still in atrial fibrillation.

This page helps you decide: The contrast case: had she stayed in sinus rhythm, what would her long-term antiplatelet therapy be at 12 months — clopidogrel or aspirin as her lifelong single antiplatelet after DAPT? (In atrial fibrillation, needing an anticoagulant, she is outside this trial.)

After this page you can

Your routine for every trial

Work through the six steps in order. Each question at the end belongs to one step, and the answer is on that step's page.

  1. Who was studied? Which patients could enter, which could not, and how sick were they?
  2. Compared with what? What did one group get that the other did not, and what was measured?
  3. What was the main result? Both percentages, the effect size with its 95% CI, and the number needed to treat (and to harm).
  4. Any design traps? Blinding, the choice of endpoint, how close the CI comes to no effect, how long it took, who paid.
  5. Does it apply to my patient? Would my patient have been allowed into the trial?
  6. What did it change? What the guideline now says, and what the trial does not tell you.

Take-home

Had Mrs. K. stayed in sinus rhythm, she would be close to the patients HOST-EXAM randomized at 12 months (event-free, inside the window, though on ticagrelor rather than clopidogrel), and clopidogrel alone would be a defensible lifelong choice (about one event prevented for every 50 treated over 2 years), though the guideline default is still aspirin 81 mg. In atrial fibrillation on an anticoagulant she was outside the trial: more than a year after PCI, the anticoagulant alone is her plan. On the one-pager it sits on page 2, in the “Beyond 12 months — longer, or which one?” box.